Brief: Idera Pharma Entered Clinical Trial Collaboration & Supply Agreement With Bristol-Myers Squibb, Effective March 11

Aceragen

13/03/2019 12:26

March 13 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * IDERA PHARMACEUTICALS - EFFECTIVE MARCH 11, CO ENTERED
CLINICAL
TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BRISTOL-MYERS
SQUIBB
    * IDERA PHARMA - WILL FUND, CONDUCT PHASE 2, OPEN-LABEL
MULTI-CENTER, MULTI-COHORT STUDY OF INTRATUMORAL TILSOTOLIMOD IN
COMBINATION WITH YERVOY, OPDIVO
    * IDERA PHARMACEUTICALS INC - BMS HAS GRANTED TO COMPANY A
NON-EXCLUSIVE, NON-TRANSFERRABLE, ROYALTY-FREE LICENSE
    * IDERA PHARMA-TO EVALUATE COMBINATION OF CO'S TLR-9
AGONIST,
TILSOTOLIMOD (IMO-2125), WITH BMS'S THERAPY YERVOY(REG)
(IPILIMUMAB) & OPDIVO(REG) (NIVOLUMAB)
    * IDERA PHARMACEUTICALS INC - BMY AGREED TO MANUFACTURE AND
SUPPLY
YERVOY AND OPDIVO, AT ITS COST AND FOR NO CHARGE TO COMPANY, FOR
USE IN TRIAL

Source text: [http://bit.ly/2XRJyF7]
Further company coverage:  BMY.N 

 (Reuters.Briefs@thomsonreuters.com)